![Paul Jackson](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Paul Jackson active positions
Companies | Position | Start | End |
---|---|---|---|
Pheon Therapeutics Ltd.
![]() Pheon Therapeutics Ltd. BiotechnologyHealth Technology Pheon Therapeutics Ltd. is an antibody drug conjugate (ADC) specialist that develops a pipeline of monotherapies for novel targets and/or with novel payloads. The company is based in Harpdenden, UK. The British company's lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types. ADCs offer the potential to treat solid tumors and liquid cancers that have not responded to other treatments. The company was founded in 2015 by Paul Jackson. Cyrus D. Mozayeni has been the CEO of the company since 2023. | Founder | 2015-07-07 | - |
Corporate Officer/Principal | - | - |
Career history of Paul Jackson
Statistics
International
United Kingdom | 2 |
Operational
Founder | 1 |
Corporate Officer/Principal | 1 |
Sectoral
Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 1 |
---|---|
Pheon Therapeutics Ltd.
![]() Pheon Therapeutics Ltd. BiotechnologyHealth Technology Pheon Therapeutics Ltd. is an antibody drug conjugate (ADC) specialist that develops a pipeline of monotherapies for novel targets and/or with novel payloads. The company is based in Harpdenden, UK. The British company's lead program is a first-in-class ADC against a novel target that is highly expressed in solid tumors across a broad range of hard-to-treat cancer types. ADCs offer the potential to treat solid tumors and liquid cancers that have not responded to other treatments. The company was founded in 2015 by Paul Jackson. Cyrus D. Mozayeni has been the CEO of the company since 2023. | Health Technology |
- Stock Market
- Insiders
- Paul Jackson
- Experience